SCHEMBL18990073

SCHEMBL18990073

Cn1c(Br)nc2c1c(=O)n(Cc1ccc(Cl)c(F)c1)c(=O)n2C

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 6/20 0.57
▸ HIF1A Q16665 5/20 0.57
▸ HPGD P15428 3/20 0.57
▸ SMN1; SMN2 Q16637 5/20 0.54
▸ LMNA P02545 3/20 0.54
▸ STAT6 P42226 2/20 0.54
▸ MAPT P10636 6/20 0.53
▸ TP53 P04637 1/20 0.53
▸ NPSR1 Q6W5P4 3/20 0.52
▸ TSHR P16473 3/20 0.52
▸ HTT P42858 2/20 0.52
▸ KMT2A Q03164 2/20 0.52
▸ MAOB P27338 1/20 0.52
▸ CYP1A2 P05177 2/20 0.52
▸ CYP3A4 P08684 2/20 0.52
▸ CYP2C9 P11712 2/20 0.52
▸ CYP2C19 P33261 2/20 0.52
▸ MTHFD2 P13995 1/20 0.51
▸ CYP2D6 P10635 1/20 0.51
▸ PKM P14618 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18990089 0.90 ALDH1A1 (0.55) ALDH1A1HIF1AHPGDSMN1; SMN2LMNA
SCHEMBL18989627 0.90 SMN1; SMN2 (0.66) ALDH1A1HIF1AHPGDSMN1; SMN2LMNA
SCHEMBL18990047 0.86 MAOB (0.55) ALDH1A1HIF1AHPGDSMN1; SMN2LMNA
SCHEMBL18990018 0.85 ALDH1A1 (0.55) ALDH1A1HIF1AHPGDSMN1; SMN2LMNA
SCHEMBL18990320 0.85 LMNA (0.65) ALDH1A1HIF1AHPGDSMN1; SMN2LMNA
SCHEMBL18990537 0.84 ALDH1A1 (0.54) ALDH1A1HIF1AHPGDSMN1; SMN2LMNA
SCHEMBL29631797 0.82 ALDH1A1 (0.60) ALDH1A1HIF1AHPGDSMN1; SMN2LMNA
SCHEMBL18990154 0.82 ALDH1A1 (0.54) ALDH1A1HIF1AHPGDSMN1; SMN2LMNA
SCHEMBL18989582 0.82 ALDH1A1 (0.60) ALDH1A1HIF1AHPGDSMN1; SMN2LMNA
SCHEMBL18989621 0.81 ALDH1A1 (0.52) ALDH1A1HIF1AHPGDSMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12187728-B2 Caffeine inhibitors of MTHFD2 and uses thereof RAZE THERAPEUTICS, INC. (US) 2025-01-07 — — US disclosed
US-20230067237-A1 CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF RAZE THERAPEUTICS, INC. 2023-03-02 — — US disclosed
US-20230067237-A1 CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF RAZE THERAPEUTICS, INC. 2023-03-02 — — US disclosed
US-11370792-B2 Caffeine inhibitors of MTHFD2 and uses thereof RAZE THERAPEUTICS, INC. (US) 2022-06-28 — — US disclosed
US-11370792-B2 Caffeine inhibitors of MTHFD2 and uses thereof RAZE THERAPEUTICS, INC. (US) 2022-06-28 — — US disclosed
US-20180370972-A1 CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF RAZE THERAPEUTICS, INC. 2018-12-27 — — US disclosed
EP-3389664-A1 CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF Raze Therapeutics Inc. (US) 2018-10-24 — — EP disclosed
WO-2017106352-A1 CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF RAZE THERAPEUTICS, INC. (US) 2017-06-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12187728-B2 Caffeine inhibitors of MTHFD2 and uses thereof MTHFD2, MTHFD1, NUDT15 ALDH1A1 260/4885HIF1A 2295/4885HPGD 188/4885
US-11370792-B2 Caffeine inhibitors of MTHFD2 and uses thereof MTHFD2, MTHFD1, NUDT15 ALDH1A1 260/4885HIF1A 2295/4885HPGD 188/4885
US-20230067237-A1 CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF MTHFD2, MTHFD1, NUDT15 ALDH1A1 260/4885HIF1A 2295/4885HPGD 188/4885
US-20180370972-A1 CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF MTHFD2, MTHFD1, NUDT15 ALDH1A1 260/4885HIF1A 2295/4885HPGD 188/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback